Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Anjulika Chawla"'
Autor:
Zora R. Rogers, Taizo A. Nakano, Timothy S. Olson, Alison A. Bertuch, Winfred Wang, Alfred Gillio, Thomas D. Coates, Anjulika Chawla, Paul Castillo, Peter Kurre, Christopher Gamper, Carolyn M. Bennett, Sarita Joshi, Amy E. Geddis, Jessica Boklan, Grzegorz Nalepa, Jennifer A. Rothman, James N. Huang, Gary M. Kupfer, Michaela Cada, Bertil Glader, Kelly J. Walkovich, Alexis A. Thompson, Rabi Hanna, Adrianna Vlachos, Maggie Malsch, Edie A. Weller, David A. Williams, Akiko Shimamura
Publikováno v:
Haematologica, Vol 104, Iss 10 (2019)
Quality of response to immunosuppressive therapy and long-term outcomes for pediatric severe aplastic anemia remain incompletely characterized. Contemporary evidence to inform treatment of relapsed or refractory severe aplastic anemia for pediatric p
Externí odkaz:
https://doaj.org/article/e30ee0ec051d4c8a8105c5d827063f09
Publikováno v:
Journal of Medical Economics. 25:1140-1148
Sickle cell disease (SCD) is a lifelong burdensome disorder of heterogenic expression. This study investigated the longer-term economic burden of severe presentation of SCD. As SCD treatment landscapes evolve toward curative intent gene therapies, un
Autor:
Mark C. Walters, Alexis A. Thompson, Janet L. Kwiatkowski, Suhag Parikh, Markus Y. Mapara, Stacey Rifkin-Zenenberg, Banu Aygun, Kimberly A. Kasow, Alex Miller, Lixin Zhang, Anjulika Chawla, Elizabeth R. Macari, Francis J. Pierciey, John F. Tisdale, Julie Kanter
Publikováno v:
Blood. 140:26-28
Publikováno v:
Pediatric Blood & Cancer. 69
Relapsed central nervous system (CNS) leukemia presents a therapeutic challenge to pediatric oncologists. Systemic monoclonal antibody therapy has shown recent promise in patients with relapsed acute lymphoblastic leukemia, however its effect on CNS
Autor:
Elizabeth E. Brown, Payal Desai, Susan Padrino, Lynne Neumayr, Anjulika Chawla, Alexandra Boye-Doe, Joshua J. Field, Jane A. Little, Charu Puri-Sharma, Deepa Manwani, Sophie Lanzkron
Publikováno v:
Blood. 136:34-36
Incremental improvement in care for children with sickle cell disease (SCD), arising from government-funded research over the last 4 decades, resulted in a dramatically reduced childhood mortality. However, the impact of iterative research and diseas
Publikováno v:
Journal of pediatric hematology/oncology. 42(8)
Background Despite advances in the treatment of sickle cell disease (SCD) in pediatric and young adult patients, pain remains a significant cause of disease-related morbidity. Physical therapy has been shown to be useful for the treatment of pain in
Autor:
Karolina Wieczorek, Raffaella Colombatti, Paul Telfer, Laura Sainati, Charu Puri-Sharma, Giulia Reggiani, Jonathan P. Bestwick, Courtney Walls, Beatrice Coppadoro, Cynthia Sangarappillai, Muriel Soriano, Sanjeev Kommera, Anjulika Chawla, Will Hann, Vania Munaretto
Publikováno v:
Blood. 138:3093-3093
Background: Hydroxyurea (HU) and chronic transfusion therapy (CTT) are the only disease modifying therapies (DMTs) currently available as standard of care in the UK and Italy for patients with sickle cell disease (SCD), with hematopoietic stem cell t
Autor:
Matthew Parkin, James Signorovitch, Elsa Tchouambou, Courtney Green, Lynn Huynh, Charu Puri-Sharma, Anjulika Chawla, Rose Chang, Gershwin Blyden, Lanetta Bronté-Hall
Publikováno v:
Blood. 134:5856-5856
Background Sickle cell disease (SCD) is a progressively debilitating monogenic disease characterized by unpredictable, acute, life-threatening episodes and chronic complications such as hemolytic anemia and end-organ damage. It presents with a range
Autor:
Peter J. Krause, Anjulika Chawla, Victor Berardi, James F. Padbury, Carolyn Young, Gail Skowron
Publikováno v:
Transfusion. 52:1523-1529
BACKGROUND: Babesiosis is the most common transfusion-transmitted infection reported to the Food and Drug Administration (FDA). We developed and implemented the first laboratory-based blood donor screening program for Babesia microti to help reduce a
Publikováno v:
Transfusion. 47:540-544
BACKGROUND: A 3½-year-old girl with Stage 4 neuroblastoma received multiple blood components and was subsequently diagnosed with Chagas disease, which is caused by Trypanosoma cruzi. STUDY DESIGN AND METHODS: All blood donors of the units that were